Umeclidinium bromide; vilanterol trifenatate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for umeclidinium bromide; vilanterol trifenatate and what is the scope of patent protection?
Umeclidinium bromide; vilanterol trifenatate
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Umeclidinium bromide; vilanterol trifenatate has three hundred and forty patent family members in forty-seven countries.
One supplier is listed for this compound.
Summary for umeclidinium bromide; vilanterol trifenatate
| International Patents: | 340 |
| US Patents: | 15 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | umeclidinium bromide; vilanterol trifenatate at DailyMed |
Recent Clinical Trials for umeclidinium bromide; vilanterol trifenatate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| SRL Mediserch.Inc | Phase 3 |
| Parexel International Japan | Phase 3 |
| GlaxoSmithKline | Phase 3 |
See all umeclidinium bromide; vilanterol trifenatate clinical trials
Pharmacology for umeclidinium bromide; vilanterol trifenatate
| Drug Class | Anticholinergic beta2-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta2-Agonists Cholinergic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for umeclidinium bromide; vilanterol trifenatate
US Patents and Regulatory Information for umeclidinium bromide; vilanterol trifenatate
Expired US Patents for umeclidinium bromide; vilanterol trifenatate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for umeclidinium bromide; vilanterol trifenatate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 1730676 | COMPTEUR A UTILISER AVEC UN DISTRIBUTEUR DE MEDICAMENT (COUNTER FOR USE WITH A MEDICAMENT DISPENSER) | See Plans and Pricing |
| Cyprus | 1114640 | See Plans and Pricing | |
| Australia | 2005215216 | Counter for use with a medicament dispenser | See Plans and Pricing |
| Morocco | 28631 | ANTAGONISTES DES RECEPTEURS MUSCARINIQUES DE L'ACETYLCHOLINE | See Plans and Pricing |
| Malaysia | 129422 | MEDICINAL COMPOUNDS | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for umeclidinium bromide; vilanterol trifenatate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1740177 | 208 50012-2014 | Slovakia | See Plans and Pricing | PRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430 |
| 2506844 | PA2018011 | Lithuania | See Plans and Pricing | PRODUCT NAME: UMEKLIDINAS + VILANTEROLIS + FLUTIKAZONO FUROATAS; REGISTRATION NO/DATE: EU/1/17/1236 20171115 |
| 1425001 | 2014C/026 | Belgium | See Plans and Pricing | PRODUCT NAME: VILANTEROL TRIFENATATE; AUTHORISATION NUMBER AND DATE: EU/1/13/886/001 20131114 |
| 1740177 | C01740177/02 | Switzerland | See Plans and Pricing | PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014 |
| 2506844 | 394 50009-2018 | Slovakia | See Plans and Pricing | PRODUCT NAME: FLUTIKAZONFUROAT / UMEKLIDINIUM / VILANTEROL VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1236/001 - EU/1/17/1236/003 20171117 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
